Open AccessSecond-line treatment with nivolumab, cabozantinib, regorafenib, or best supportive care in patients with advanced hepatocellular carcinoma: analysis at a Hispanic-majority NCI-designated cancer center
Journal Of Gastrointestinal OncologyPeer ReviewedJeffrey Xia +22021Journals
The content you want is available to Zendy users.
Already have an account? Sign inHaving issues? Contact support